NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its ...
PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System
First three patients underwent successful implantation and clinical utilization of PortIO as part of a first-in-human study in Colombia, South America NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: ...
Potential Savings of $95 Million Annually if Only Ten Percent of Central Lines Are Replaced with IO Access Success rate of 96% in establishing vascular access on first attempt; Mean time to vascular ...
March 11, 2008 — The US Food and Drug Administration (FDA) has granted 510(k) clearance for a handheld device for the measurement of airway inflammation, an intraosseous infusion system for use in ...
Pavmed Inc. implanted its Portio system in three patients in a first-in-human (FIH) study of its intraosseous infusion system and successfully infused fluids in all patients without complications. The ...
PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System
NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced that physicians at the Clinica ...
FDA pre-submission meeting date supporting de novo application secured Broad method and device patents granted by USPTO NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ...
PAVmed Inc (NASDAQ: PAVM) announced the successful implantation of its PortIO Intraosseous Infusion System in three patients as part of a first-in-human (FIH) clinical study of up to 40 patients. No ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback